Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment
Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment
Lymphoma
#CART #CellDiscovery #Lymphoma #BCellLymphoma #RRLBCL #IL7 #CCL19
In recent years, China has made significant progress in medical innovation, especially in the field of Chimeric Antigen Receptor T-cell (CAR-T) therapy, dramatically changing the landscape of treatment for malignant blood cancers. Recently, a team of medical professors from Zhejiang, China, released the results of a clinical trial demonstrating the breakthrough effectiveness of fourth-generation anti-CD19 CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study, published in the renowned journal *Cell Discovery* (“Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma”), sheds light on this innovative approach.
**New Highlights of CAR-T Therapy**
Traditional anti-CD19 CAR-T cell therapy has already shown excellent efficacy in treating blood cancers like R/R LBCL, but tumor relapse remains a significant challenge. To address this, Chinese researchers have developed a new fourth-generation CAR-T cell therapy that co-expresses two cytokines, IL-7 and CCL19. These cytokines enhance the activity of immune cells, improving CAR-T cells’ anti-tumor effects and extending patient survival.
**Efficacy and Potential**
The Chinese medical team included 39 patients, aged 29 to 73, in this study. They received a single infusion of the fourth-generation anti-CD19 CAR-T cells co-expressing IL-7/CCL19. The results showed that within three months of treatment, the overall response rate (ORR) reached 79.5%, with a complete response rate (CR) of 56.4%. This therapy also demonstrated a notable long-lasting effect, with a median progression-free survival (PFS) of 13 months, and an estimated two-year overall survival rate (OS) of 53.8%.
The study found that the expansion of CAR-T cells in the blood and plasma levels of IL-7/CCL19 were closely associated with clinical outcomes. Higher CAR-T cell expansion and peak concentrations of IL-7/CCL19 were linked to better overall survival (OS), further confirming that this combination can enhance CAR-T cells’ anti-tumor potential.
**Why Is This Study So Important?**
The introduction of this new CAR-T therapy in China marks a significant leap forward in cancer treatment. It not only induces long-lasting remission but also significantly extends patient survival, with manageable safety, offering new hope to patients facing resistant blood cancers. China’s rapid advancements in CAR-T technology showcase its growing influence in the global biotechnology sector.
This groundbreaking research not only solidifies China’s important position in medical innovation but also lays the foundation for future development and application of more CAR-T therapies, potentially bringing revolutionary changes to cancer treatment worldwide.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CAR_Therapy #CancerTreatment #MedicalInnovation #BCellLymphoma #ChinaBiotech #Immunotherapy #FourthGenerationCAR_T #BloodCancer #CytokineTherapy #OncologyBreakthrough #CellDiscovery #CancerResearch #TumorImmunology #PatientSurvival #Hematology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**
**CAR-T Therapy: A New Hope for Effective Immunotherapy or an Expensive Challenge?**
As an innovative immunotherapy, CAR-T therapy has gradually become available in China in recent years, attracting significant attention from patients. Although it is dubbed the “million-dollar therapy” due to its high cost, experts emphasize that CAR-T is not a conventional drug but a “living drug.” Its effectiveness is confirmed, but the outcome largely depends on the skill and experience of the operator. Like a horse-riding competition, the handler must fully understand and control this “good horse.” Early data show promising results, and while the overall treatment cost remains high, its efficacy is undeniable.
To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**
**The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma**
patient story
In the long journey of life, cancer often strikes like a sudden storm, leaving patients and their families devastated. Mrs. Li, a young and resilient mother from China, was no exception. Two years ago, she was diagnosed with relapsed and refractory B-cell non-Hodgkin lymphoma. The shocking news felt like a bolt from the blue, throwing her once-happy family into the depths of despair.
Traditional chemotherapy and radiation therapy once brought a flicker of hope for Mrs. Li, temporarily alleviating her condition. However, fate seemed to play a cruel trick on her again, as the tumor returned with more aggression, no longer responding to conventional treatments. The repeated rounds of therapy took a toll on her body and spirit. Both Mrs. Li and her family were pushed to the brink of collapse, feeling trapped in a deep abyss with no light of hope in sight.
Just when Mrs. Li was about to give up, fate intervened. Thanks to the relentless efforts of the “Advanced Medicine in China” team, they successfully connected Mrs. Li with the country’s top hematology specialists. After a series of communications and coordination, this expert became her last lifeline, taking on the responsibility of devising the best treatment plan during her darkest hours.
After conducting a comprehensive and detailed examination of Mrs. Li, the expert, relying on extensive experience and professional judgment, decisively recommended CAR-T therapy, a cutting-edge treatment. This innovative immunotherapy acts like a magical key, reactivating the patient’s immune system to precisely target and attack cancer cells, offering a new glimmer of life. Faced with this final hope, Mrs. Li carefully considered her options and bravely decided to seize it, determined to fight once more for her life.
The results were truly remarkable. CAR-T therapy produced astonishing effects in Mrs. Li, like a dazzling light in the darkness. After just a few weeks, follow-up tests showed that her tumor had significantly shrunk, and the symptoms that had once plagued her improved dramatically. This was a pivotal moment, allowing Mrs. Li and her family to rediscover hope for the future.
In the months that followed, under close monitoring and consolidation treatment, Mrs. Li’s condition stabilized, as though the ferocious beast of cancer had been tamed. Ultimately, she achieved a miracle—her cancer reached complete remission. For Mrs. Li and her family, this was nothing short of extraordinary, filling their hearts with overwhelming joy and gratitude. They were not only rekindled with the flame of hope for life but also deeply thankful to the “Advanced Medicine in China” team and CAR-T therapy.
As the recommending team, “Advanced Medicine in China” feels honored to have witnessed Mrs. Li’s recovery journey. This is not just a victory for one patient but a successful step forward in the ongoing battle against cancer, inspiring the team to continue seeking rays of hope for more patients. Mrs. Li’s story has become a powerful tale of triumph, spreading rapidly among fellow patients. Her courage and perseverance have set an example for many others bravely fighting blood cancer, encouraging them to press on and never give up.
Through Mrs. Li’s case, CAR-T therapy in China has once again demonstrated its immense potential in the treatment of lymphoma. Like a rising star, it is bringing new hope to blood cancer patients worldwide, illuminating their path toward overcoming the disease. In the future, CAR-T therapy in China will undoubtedly create more miracles, offering patients the dawn of life and a brighter future.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#patientstory #CARTTherapy #CancerSurvivor #Lymphoma #LymphomaTreatment #BloodCancerAwareness#MedicalMiracles #ChinasMedicalAdvances #CancerResearch #PatientStories #HopeAgainstCancer #Immunotherapy #FightCancer #CancerRemission #CourageToFight #BreakthroughInMedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting
**China Leads the CAR-T Therapy Revolution, Reshaping the Treatment Landscape of Large B-Cell Lymphoma—2024 CSCO Annual Meeting**
CSCO
#CSCO #CSCO2024 #Lymphoma #CART #LBCL #RRLBCL #ChinaCAR-T
At the 27th Annual Chinese Society of Clinical Oncology (CSCO) Conference, held in Xiamen, China, CAR-T therapy took center stage as a key focus for the treatment of large B-cell lymphoma (LBCL). As a Chimeric Antigen Receptor T-cell (CAR-T) therapy, this innovative approach is revolutionizing the treatment of relapsed/refractory large B-cell lymphoma (R/R LBCL), offering new hope for patients where traditional therapies have been less effective.
### Breakthroughs in CAR-T Therapy for LBCL
As a major innovation in immunotherapy, CAR-T therapy has shown remarkable efficacy in treating R/R LBCL. Clinical data indicates that about one-third of R/R LBCL patients can achieve long-term remission or even cure through CAR-T therapy. Notably, Axicabtagene ciloleucel (Axi-cel), developed by Fosun Kite Biotechnology, is the first domestically approved CD19-targeted autologous CAR-T product in China. Six-year follow-up results revealed that the two-year overall survival rate was 50.5%, and the six-year lymphoma event-free survival rate was 33.5%.
Meanwhile, Relma-cel, a CAR-T product independently developed by JW Therapeutics in China, has also achieved impressive results. Two-year follow-up data showed a median duration of response of 20.3 months, further highlighting China’s growing research and manufacturing strength in the CAR-T therapy field.
### CAR-T Therapy Expands from Third-Line to Second-Line Use
While CAR-T therapy was initially used only for patients who had failed multiple lines of treatment, it is now being increasingly applied in second-line settings. Recent studies have shown that CAR-T therapy outperforms traditional high-dose chemotherapy and autologous stem cell transplant (ASCT) in certain patient groups. For example, the ZUMA-7 study demonstrated that Axi-cel significantly improved event-free survival (EFS) for LBCL patients treated in the second-line setting, with a median EFS of 8.3 months, compared to 2 months in the ASCT group.
As more research progresses, CAR-T therapy has been recommended by leading clinical guidelines, such as the National Comprehensive Cancer Network (NCCN), for use in patients with primary refractory or early relapsing LBCL. This shift underscores CAR-T’s growing role in earlier stages of treatment, providing more therapeutic options for patients.
### Challenges and Future Prospects
In the exploration of CAR-T as a first-line treatment, promising results are beginning to emerge. The ZUMA-12 study evaluated the use of Axi-cel in high-risk LBCL patients in the first-line setting, with a three-year follow-up showing an overall survival rate of 90.6%. These findings suggest that CAR-T therapy could become an important treatment option for high-risk patients even in the first-line setting.
### China’s Leading Role in CAR-T Therapy
China is rapidly emerging as a global leader in the development and commercialization of CAR-T therapy. With domestically developed products like Axi-cel and Relma-cel achieving significant progress both in China and globally, China’s competitive edge in this field is becoming increasingly evident. As the technology matures and more clinical data are released, the future of CAR-T therapy in LBCL treatment looks exceptionally bright.
The 2024 CSCO Annual Meeting showcased China’s strong commitment to advancing CAR-T therapy. As breakthroughs and challenges coexist, CAR-T therapy is poised to continue playing a critical role in the treatment of large B-cell lymphoma, with China leading the way in this global medical revolution.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#LymphomaTreatment #ImmunotherapyRevolution #CancerResearch #MedicalInnovation #BCellLymphoma
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL
**Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL**
T-ALL
#CAR-TTherapy #TALL #ALL #Leukemia #RelapsedLeukemia #TCellLeukemia #CD5 #CD7 #CART
Recently, a collaborative research study conducted by multiple Chinese medical and research institutions was published in *Nature Medicine*. This study, titled “Allogeneic CD5-specific CAR-T Therapy for Relapsed/Refractory T-ALL: A Phase 1 Trial,” demonstrated the potential of CD5 CAR-T cells in treating relapsed/refractory acute T-cell lymphoblastic leukemia (R/R T-ALL).
### Innovative Therapy Brings Hope
For a long time, patients with relapsed/refractory T-ALL have lacked effective treatment options and faced a poor prognosis. In recent years, CD7 CAR-T cell therapy has shown some efficacy in these patients, but CD7-negative relapse remains a significant challenge. This study focuses on evaluating the safety, efficacy, and pharmacokinetics of CD5 CAR-T cells, offering new insights for future treatments.
The study included 19 patients, most of whom had previously received CD7 CAR-T therapy. Results showed that this therapy was safe, with no dose-limiting toxicity observed, and adverse events were primarily manageable hematologic toxicity. In terms of efficacy, all patients achieved complete remission within 30 days of treatment. The study also demonstrated, for the first time, the persistence of CD5 CAR-T cells in the body and their ability to eliminate CD5+ T cells, indicating strong anti-tumor activity.
### Breakthrough in Treating Relapsed Patients
In addition to safety and efficacy, the research team explored the coexistence of CD7 CAR-T and CD5 CAR-T cells and studied immune cell changes in the patients. For those who relapsed after CD7 CAR-T treatment with CD7-negative cells, CD5 CAR-T offered a new salvage therapy, providing additional treatment options for such patients.
### Multidisciplinary Collaboration Drives Clinical Progress
Unlike CAR-T therapies for B-cell tumors, treating T-cell malignancies poses more challenges, particularly in controlling immune deficiencies. Dr. Jing Pan and her team conducted in-depth research on target selection and relapse mechanisms, while also focusing on balancing treatment safety and efficacy.
This study was made possible by the collaborative efforts of various medical institutions in China, collectively opening up a new therapeutic pathway for T-cell tumor patients.
### Looking Ahead
As innovations and advances in T-ALL treatment continue, the team plans to further research CD5 CAR-T therapy and collaborate with experts across various fields to optimize CAR-T treatment protocols, helping more patients with T-cell lymphoblastic tumors overcome their diseases.
This series of research achievements not only brings new hope to patients with R/R T-ALL but also provides valuable insights for the future development and optimization of CAR-T therapies. The team remains committed to a patient-centered approach, striving to drive continuous breakthroughs and innovations in T-cell tumor treatment.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#Immunotherapy #CancerTreatment #TALLResearch #LeukemiaBreakthrough #Hematology #CellTherapy #CancerInnovation #CancerResearch #ClinicalTrials #MedicalBreakthrough
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients
### China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients
CAR-T Therapy
Multiple myeloma remains a difficult-to-cure disease, and every year, countless patients around the world face this devastating diagnosis. While treatment options have improved in recent years, and patients’ survival times have extended, drug resistance remains a significant challenge. For patients who have experienced multiple relapses and are resistant to various treatments, the future can seem bleak. Fortunately, with the emergence of **BCMA CAR-T cell therapy**, a new ray of hope is illuminating the path for these patients.
This is the story we’re sharing today, about a 76-year-old female patient who regained control of her life through CAR-T therapy.
#### The First Encounter with the Disease
In 2020, this Chinese 76-year-old woman noticed a decline in appetite and a rapid weight loss, accompanied by persistent rib pain. She had no idea that these symptoms were early signs of multiple myeloma. After several medical tests, her Chinese doctors confirmed the diagnosis: 31% of her bone marrow cells were plasma cells, her M-protein levels reached 85.7 g/L, and calcium levels in her blood were abnormally high. Multiple bones throughout her body also showed signs of significant damage.
The diagnosis left the patient shocked and confused. Multiple myeloma wasn’t her first health challenge; she also had a history of Parkinson’s disease. However, she remained hopeful, believing that with the right treatment, her condition could be controlled. But fate had other plans.
#### The Struggle and Relapse
At the beginning of 2023, the patient’s condition relapsed rapidly. Due to a prolonged lack of regular treatment, her disease worsened, and she became resistant to many standard therapies. After extensive tests, her medical team discovered that she had a high-risk mSMART 3.0 profile, with genetic abnormalities including 1q21 amplification and a t(4;14) translocation, making her prognosis extremely poor. She was now considered a “triple-refractory” patient, resistant to three main treatment categories.
Faced with this complex and challenging situation, the Chinese doctors didn’t give up. After multiple discussions and research, they recommended a cutting-edge therapy — **BCMA CAR-T cell therapy**. This treatment involves modifying the patient’s immune cells to target and destroy cancer cells. However, to undergo this advanced therapy, the patient first needed to undergo **bridging treatment** to reduce the tumor burden in her body.
#### Bridging Treatment: A Turning Point
To prepare for CAR-T therapy, the Chinese doctors initially prescribed the **DKD regimen**, a combination therapy intended to quickly reduce the cancer cell load. However, the first treatment cycle didn’t bring significant improvement, and her free light chain levels remained high. Both the patient and her family felt disappointed, but the Chinese doctors acted quickly, switching to the **KAD regimen**, which included **liposomal doxorubicin** to further enhance the treatment’s effectiveness.
This adjustment brought immediate results. After a few weeks, her free light chain levels began to drop, and her condition showed partial remission (PR). This meant she was finally ready for CAR-T cell therapy.
#### The Miracle of CAR-T Therapy
CAR-T therapy is a breakthrough technology where the patient’s immune cells are extracted, genetically modified to recognize and destroy cancer cells, and then reintroduced into the body. These engineered cells act like precision-guided weapons, specifically targeting her cancer cells.
The patient responded positively to the treatment. Within just a few weeks, her condition was significantly controlled, with results showing a very good partial response (VGPR). For such a complex case of relapsed and refractory disease, this was a major success.
#### The Significance of the Story
This patient’s story highlights China’s latest advancements in the treatment of multiple myeloma. The use of **carfilzomib-based bridging therapy** paved the way for CAR-T therapy, successfully giving a patient with a poor prognosis a new chance at life. For those facing the dual challenges of drug resistance and relapse, **BCMA CAR-T therapy** offers not just a new treatment option, but a lifeline.
The product that has renewed hope for this 76-year-old Chinese woman is a BCMA-targeted CAR-T therapy that has already been launched in China. China is changing the fate of patients worldwide through advanced cancer treatments. Notably, in the field of CAR-T technology related to hematologic tumors and multiple myeloma, two BCMA CAR-T products have been approved in China. Especially commendable is Reindeer Bio’s independently developed fully human BCMA product, FUCASO, which has achieved an astonishing complete remission (CR) rate of 82.4%, the highest among all globally approved products. An increasing number of foreign multiple myeloma patients are now seeking treatment in China to access better therapies at more affordable prices. As China continues to develop cutting-edge medical therapies, aggressive treatments like CAR-T undoubtedly provide new hope for the future of multiple myeloma treatment.
Follow us for more stories of medical innovation and to witness how miracles of life are born in China!
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#MultipleMyeloma #CancerTreatment #CAR_TTherapy #BCMACAR_T #CancerSurvivor #Immunotherapy #ChinaMedicalInnovation #CancerResearch #CancerHope #MedicalBreakthrough #MyelomaAwareness #AdvancedCancerCare #RelapsedMyeloma #LifeSavingTreatment #PatientSuccessStory #CancerCare #GlobalHealth #CAR_TSuccess #Oncology #CancerSupport
#ChineseMedical #ChinaHealthcare #MedicalCareInChina #HealthcareInChina · #USMedical #USHealthcare #HealthcareInUSA #AmericanMedical #MedicalCareInUSA #USAHealth #AmericanHealthcare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Why Does China Have a Unique Advantage in the Field of CAR-T Therapy?
**Why Does China Have a Unique Advantage in the Field of CAR-T Therapy?**
CAR-T
#CAR_Therapy #CancerTreatment #MedicalInnovation #ChinaMedical
In recent years, China has made rapid advancements in medical technology, particularly in the area of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This cutting-edge cancer treatment involves reprogramming a patient’s own T cells to recognize and attack cancer cells. This revolutionary therapy has transformed treatment options for various malignancies, with China’s innovations and applications standing out globally.
### 1. **Scientific Innovation and Technological Breakthroughs**
China has reached a world-leading level in CAR-T research and development. Numerous prestigious medical schools and research institutions in China have actively contributed to this field, leading to the creation of several novel CAR-T treatment methods. Chinese scientists have pioneered significant innovations in CAR-T cell engineering, toxicity control, and target selection. For example, the CD19 CAR-T therapy for hematologic malignancies is widely used in China. Additionally, the fully human BCMA-targeted CAR-T product, Equecabtagene Autoleucel, used for multiple myeloma, has achieved a complete remission (CR) rate of 82.4%. Recently, *Nature* featured China’s breakthrough in using universal CAR-T for autoimmune diseases. New CAR-T therapies targeting solid tumors are also progressing rapidly.
### 2. **Cost-Effectiveness and Extensive Clinical Application**
Compared to some Western countries, CAR-T therapy in China is more affordable, partially due to lower production and R&D costs. A surge of local pharmaceutical and biotech companies has emerged, promoting the domestic production of CAR-T products and reducing reliance on imported drugs. This efficient supply chain management has not only lowered treatment costs but also made the personalized therapy more accessible to patients. While CAR-T therapy in the U.S. can cost $700,000–$800,000, the cost in China is about one-fifth to one-seventh of that.
Moreover, the faster approval process for clinical trials in China enables researchers to quickly bring new therapies to market, allowing patients earlier access to innovative treatments. This efficiency is supported by streamlined regulatory frameworks and healthcare reforms.
### 3. **Government Policy Support and International Collaboration**
The Chinese government has implemented various policies to strongly support biomedical innovation, including the development and application of CAR-T technology. For example, the National Medical Products Administration (NMPA) has accelerated the approval process for CAR-T therapies, simplifying regulatory procedures, and encouraging international cooperation and technology transfer. Many international pharmaceutical giants have partnered with Chinese companies to jointly advance CAR-T therapy research and commercialization. This openness has established China as a key global center for CAR-T treatment.
### 4. **Large Patient Population Driving Research and Application**
As the most populous country, China has a vast cancer patient population, providing abundant clinical cases and research resources for the application and further optimization of CAR-T therapy. This large patient base allows China to conduct large-scale clinical trials in a short time, accelerating the validation of treatment effectiveness and maturity. In China, not only are there local consensus guidelines for CAR-T usage, but each physician applying CAR-T has significant experience in both initial treatments and post-therapy management.
### 5. **Interdisciplinary Collaboration and Development**
China’s advancements in cellular immunotherapy are not solely dependent on progress in medical fields but are also supported by the integration of interdisciplinary technologies such as artificial intelligence, gene editing, and materials science. For instance, AI is increasingly playing a role in optimizing and personalizing CAR-T therapy designs. Gene editing tools like CRISPR are also widely applied in China for designing CAR-T cells, making them more precise and effective.
### Conclusion
China’s unique advantages in CAR-T therapy stem from continuous scientific breakthroughs, lower treatment costs, strong government support, and a vast patient base. As technology advances and international collaborations deepen, China is poised to play an increasingly important role in the global fight against cancer. CAR-T therapy offers new hope to cancer patients, and China’s innovation and strength are helping bring this hope to fruition sooner.
This is not just China’s advantage; it is a blessing for cancer patients worldwide.
🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#ChimericAntigenReceptor #CancerResearch #Immunotherapy #ChinaMedicalAdvancements #Biotech #GeneTherapy #CellTherapy #HealthcareRevolution #CancerCare #AIinHealthcare #PrecisionMedicine #GlobalHealth
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Nature Headline! China’s CAR-T Therapy Breakthrough Leads the World—A New Hope for Autoimmune Disease Treatment
🌟 **Nature Headline!** China’s CAR-T Therapy Breakthrough Leads the World—A New Hope for Autoimmune Disease Treatment
Autoimmune
#CAR_Therapy #CRISPR #AutoimmuneDisease #Immunotherapy #Nature #Autoimmune #IMNM #dcSSc #immunemediatednecrotizingmyopathy #cutaneoussystemicsclerosis
💪 Chinese medical scientists have made a major breakthrough in treating autoimmune diseases with revolutionary CAR-T therapy. This study, conducted by scientists from three Chinese universities, was published in the prestigious journal *Cell* on October 04, 2024. It is the first study to use universal CAR-T cells derived from healthy donors, successfully helping three autoimmune disease patients achieve long-term remission. This marks a new era in treating difficult-to-treat autoimmune diseases globally.
📈 Traditional CAR-T therapies are primarily used to treat cancer, relying on extracting immune cells from patients, modifying them genetically, and reinfusing them—an expensive and complex process. However, the Chinese research team developed a next-generation CAR-T therapy that uses gene-editing technology to modify donor-derived T cells. These cells can be mass-produced and are ready for immediate use. This new approach not only significantly reduces treatment costs but also shortens the preparation time.
In this study, three patients with severe autoimmune diseases received the universal CAR-T therapy, including a 57-year-old male patient, Mr. Gong, who suffered from systemic sclerosis. Just three days after treatment, his skin showed noticeable improvement, and he regained movement in his fingers. Two weeks later, he returned to work. Now, over a year of follow-up later, Mr. Gong’s condition remains stable, and he says he “feels great.” This demonstrates the therapy’s potential for long-term effectiveness and safety.
The development of this next-generation CAR-T therapy uses CRISPR-Cas9 gene-editing technology, allowing the modified cells to target and eliminate B cells—critical players in various autoimmune diseases. After treatment, the diseased B cells disappeared from patients, and healthy B cells regenerated, all without the occurrence of common severe side effects like cytokine release syndrome.
This achievement not only brings new hope for autoimmune disease treatment but also paves the way for future applications of CAR-T cell therapy. As clinical trials continue, more patients are expected to benefit from this groundbreaking treatment.
🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CAR_Therapy #GeneEditing #CRISPR #MedicalBreakthrough #AutoimmuneDisease #Immunotherapy #StemCellResearch #CellTherapy #Biotech #FutureOfMedicine #MedicalInnovation #HealthRevolution #ChineseScience #CancerResearch #MedicalTechnology #PrecisionMedicine #GlobalHealth #ScienceNews #HealthInnovation #CureForAll
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s New CAR-T Therapy ssCART-19: Exceptional Safety with Zero ICANS Incidence
China’s New CAR-T Therapy ssCART-19: Exceptional Safety with Zero ICANS Incidence
CARTTherapy
#ssCART19 #CAR_T #CART #ALL #ICANS #CNSL #CARTTherapy
CAR-T therapy has reached another breakthrough with the introduction of ssCART-19, a new treatment that leverages IL-6 gene silencing technology to significantly reduce side effects, particularly when treating relapsed/refractory acute lymphoblastic leukemia (r/r ALL). Unlike traditional CAR-T therapies, ssCART-19 drastically lowers the risks of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
In the latest clinical trials, ssCART-19 demonstrated outstanding safety, with no patients experiencing ICANS, marking a milestone in CAR-T therapy safety. Among the 17 patients treated, 58.8% showed a significant increase in cell counts, and no cases of Grade 4 or higher CRS were reported. Additionally, ssCART-19 achieved an overall response rate (ORR) of 87.5% within three months, with nearly 63% of patients reaching complete remission.
The latest research also highlights that ssCART-19 outperforms traditional CAR-T products (cCART-19) in both safety and efficacy. Compared to conventional therapies, ssCART-19 significantly reduced the incidence of severe CRS, neutropenia, and ICANS, achieving an ORR of 91.5%. With these impressive results, ssCART-19 is expected to become a groundbreaking option for treating r/r ALL, offering new hope, especially for patients with central nervous system leukemia (CNSL).
Developed by a Chinese biopharmaceutical company, ssCART-19 has gained widespread recognition on the international stage, receiving Orphan Drug designation from the U.S. FDA and being listed as a breakthrough therapy in China. ssCART-19 offers a new treatment option for patients previously excluded from CAR-T therapy, greatly enhancing their chances of survival.
Stay tuned for more updates on how ssCART-19 is transforming cancer immunotherapy.
To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CART #CancerTreatment #Leukemia #BreakthroughTherapy #InnovativeMedicine #Immunotherapy #CancerResearch
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Can the Million-dollar Anti-cancer Injection “Cure” Tumors?
Can the Million-dollar Anti-cancer Injection “Cure” Tumors?
Is CAR-T therapy really a “one-shot cure”?
And how can we ensure that this CAR “drives well and drives long”?
百万抗癌针能“治愈”肿瘤吗?
如何让CAR“开得好，开得久?”
Expert：
**Jing Pan**
**Associate Chief Physician**
**Department of Pediatric Hematology, Beijing Gaobo Hospital**
**Professional Memberships:**
– Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association
– Youth Committee Member, Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association
– Youth Committee Member, Clinical Application Professional Committee of the Chinese Medical Biotechnology Association
**Expertise:**
Dr. Pan currently manages an 80-bed pediatric hematology unit and has extensive experience in pediatric hematology, particularly in CAR-T cell immunotherapy, with nearly 10 years of experience in the field. She is dedicated to stratified CAR-T treatment, optimizing the management of complications during CAR-T therapy, and establishing an efficacy monitoring system post-treatment. Dr. Pan and her team have accumulated one of the largest single-center case collections globally, particularly in the areas of sequential CAR-T therapy for improving long-term outcomes in B-ALL and in exploring autologous and allogeneic CD5, CD7 CAR-T therapy for T-ALL/LBL.
Her related clinical research on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and CD19-22 sequential CAR-T has been published in leading international journals such as *Lancet Oncology*, *JCO*, *Blood*, *JHO*, and *Leukemia*. Additionally, she has frequently presented the latest advancements in her team’s immunotherapy research at both domestic and international conferences, including ASCO, ASH, EHA, and JSH.
潘 静
副主任医师
北京高博医院 小儿血液科
中国抗癌协会小儿肿瘤专业委员会专业委员
中国抗癌协会血液肿瘤专业委员会青年委员
中国医药生物技术协会医药生物技术临床应用专业委员会青年委员
擅长:
目前独立管理床位数80张的儿童血液病区。从事儿童血液科临床工作多年，特别是在儿童CAR-T细胞免疫治疗方面积累了近10年的经验。致力于CAR-T的分层治疗，优化CAR-T治疗过程中的并发症处理，建立CAR-T治疗后的疗效监控体系。尤其是其带领团队在序贯CAR-T提高B-ALL远期预后，T-ALL/LBL的自体、异体CD5、CD7CAR-T治疗探索方面目前积累了全球较大的单中心病例数。相关的CD7CAR-T临床研究、CD19CAR-T临床研究、CD22CAR-T临床研究、CD19-22序贯CAR-T研究等，发表在国际血液病权威杂志期刊Lancet on-cology、JC0、Blood、JHO和Leukemia。并多次在国内外学术会议(美国临床肿瘤大会ASCO、美国血液年会ASH、欧洲血液年会EHA、日本血液年会JSH)汇报团队免疫治疗的最新进展。
To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**
**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**
Lupus
#LupusTreatment #HopeForLupus #lupus #AutoimmuneDisease #ChinaHealthcare #SystemicLupusErythematosus #Erythematosus #patientstory #SLE
In June 2024, 13-year-old Qingqing experienced a major turning point in her life. A year after being diagnosed with systemic lupus erythematosus (SLE), she received innovative CAR-T therapy at Shanghai Children’s Medical Center and successfully achieved disease remission. SLE, often referred to as the “incurable cancer,” is an autoimmune disease that affects millions of people worldwide, severely damaging the brain, lungs, kidneys, and blood system. Even when not in an acute flare, patients often suffer from chronic symptoms such as fatigue, rashes, pain, and fever.
Qingqing’s treatment marks a significant breakthrough in the global fight against SLE. Previously, SLE patients could only rely on lifelong medications, such as steroids and immunosuppressants, to control the disease and prevent severe complications. However, these drugs often come with side effects and long-term organ damage. Qingqing’s case has offered the world new hope. A team led by Dr. Li Benshang, chief physician of the Hematology and Oncology Department, and Dr. Yin Lei, head of the Nephrology Department, pioneered the use of CAR-T therapy in SLE treatment and initiated a clinical study. After just two months of treatment, Qingqing’s condition has fully gone into remission, and all medications were discontinued.
CAR-T therapy was originally used in cancer treatment by extracting a patient’s T cells and genetically modifying them to recognize and kill abnormal cells in the body. In the treatment of SLE, CAR-T therapy eliminates the abnormal plasma cells producing autoantibodies, effectively “resetting” the patient’s immune system and addressing the root cause of the disease.
Qingqing’s success story is not only a milestone in China’s CAR-T technology but also a major leap forward in the global treatment of autoimmune diseases like SLE. Since the first CAR-T treatment cured an SLE patient in 2021, numerous clinical trials have been conducted worldwide, and several Chinese hospitals have also achieved success. However, while early results are encouraging, further research and validation are needed to confirm the long-term safety and efficacy of the treatment.
With 20% of the global population affected by various types of autoimmune diseases, CAR-T therapy holds the potential to bring new life to millions of patients. China’s ongoing research and international collaboration in this field offer unprecedented hope for overcoming persistent diseases like SLE.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
(Https://wa.me/+8613717959070)
Email: doctor.huang@globecancer.com
#CAR-Ttherapy #LupusTreatment #AutoimmuneDisease #MedicalInnovation #ChinaHealthcare #Immunotherapy #CancerTreatment #HealthBreakthrough #HopeForLupus #FutureOfMedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)
CAR-T Therapy in China: Relma-cel Offers Deep and Lasting Remission for Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)
MCL